Clinical trial
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised…
NCT00292435 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00292435 |
|---|---|
| Title | Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI) |
| Official title | A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Venous Insufficiency |
| Intervention type | Drug |
| Interventions | Read vine leaf extract (AS 195) |
| Enrollment | 202 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2006 |
| First posted | Feb 16, 2006 |
| Last update posted | Oct 29, 2013 |
| Countries | Austria, Czechia, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: